Eric Bjerkholt Sells 1,053 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CFO Eric Bjerkholt sold 1,053 shares of the business’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $96.19, for a total value of $101,288.07. Following the sale, the chief financial officer owned 43,741 shares in the company, valued at approximately $4,207,446.79. This represents a 2.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Eric Bjerkholt also recently made the following trade(s):

• On Thursday, January 22nd, Eric Bjerkholt sold 1,421 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $93.33, for a total value of $132,621.93.

Mirum Pharmaceuticals Stock Up 1.6%

MIRM opened at $100.85 on Thursday. The company has a market capitalization of $5.18 billion, a P/E ratio of -117.27 and a beta of 0.48. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.31 and a quick ratio of 3.16. The firm’s fifty day moving average price is $78.97 and its two-hundred day moving average price is $71.75. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $101.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.05 EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.15. Mirum Pharmaceuticals had a negative net margin of 8.78% and a negative return on equity of 16.47%. The company had revenue of $133.01 million during the quarter, compared to the consensus estimate of $130.11 million. During the same period last year, the firm earned ($0.30) EPS. The firm’s revenue for the quarter was up 47.1% compared to the same quarter last year. On average, analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Trending Headlines about Mirum Pharmaceuticals

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Director Patrick J. Heron bought 131,425 shares at $68.48 (~$9.0M), increasing his stake ~40% — a strong insider vote of confidence that typically supports share demand. Heron Form 4
• Positive Sentiment: HC Wainwright reiterated a Buy and raised its price target (reported lift to $130) while publishing bullish long‑term EPS projections (notably aggressive FY2030 and FY2029 estimates), which supports higher valuation expectations and likely attracted momentum buyers. Analyst Upgrade / 52‑Week High
• Positive Sentiment: Mirum completed its acquisition of Bluejay Therapeutics, expanding its rare‑disease pipeline and potential future revenue streams — a strategic corporate development investors view as accretive. Acquisition Announcement
• Neutral Sentiment: HC Wainwright adjusted near‑term EPS forecasts (cut FY2027 and trimmed FY2028 modestly) while raising longer‑range estimates — mixed guidance that tempers but does not negate the bullish long‑term thesis. HC Wainwright Estimates
• Negative Sentiment: Several senior executives sold stock on Jan 26 at about $96.19: CEO Christopher Peetz (6,831 shares, ≈$657K), COO Peter Radovich (3,143 shares), CFO Eric Bjerkholt (1,053 shares), and SVP Jolanda Howe (842 shares). Multiple insider sales on the same day can raise near‑term investor caution about insider liquidity needs despite the large director buy. CEO Form 4 COO Form 4 CFO Form 4 SVP Form 4

Hedge Funds Weigh In On Mirum Pharmaceuticals

Several institutional investors have recently bought and sold shares of the business. Emerald Advisers LLC raised its position in shares of Mirum Pharmaceuticals by 20.9% during the third quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares during the last quarter. Jump Financial LLC boosted its holdings in Mirum Pharmaceuticals by 839.7% in the second quarter. Jump Financial LLC now owns 148,689 shares of the company’s stock valued at $7,567,000 after acquiring an additional 132,866 shares during the last quarter. Campbell & CO Investment Adviser LLC acquired a new stake in Mirum Pharmaceuticals in the third quarter worth about $1,728,000. Eventide Asset Management LLC raised its holdings in Mirum Pharmaceuticals by 4.4% during the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock worth $134,224,000 after purchasing an additional 110,485 shares during the last quarter. Finally, Emerald Mutual Fund Advisers Trust acquired a new position in Mirum Pharmaceuticals during the 2nd quarter valued at about $11,071,000.

Analyst Ratings Changes

MIRM has been the topic of several analyst reports. JMP Securities set a $95.00 price objective on Mirum Pharmaceuticals in a research note on Wednesday, November 5th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $110.00 price target on shares of Mirum Pharmaceuticals in a research note on Thursday, December 11th. HC Wainwright increased their price objective on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday. Wall Street Zen raised Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. Finally, TD Cowen restated a “buy” rating on shares of Mirum Pharmaceuticals in a research note on Monday, January 12th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $104.92.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.